153 related articles for article (PubMed ID: 8781438)
21. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines.
Damiano JS; Cress AE; Hazlehurst LA; Shtil AA; Dalton WS
Blood; 1999 Mar; 93(5):1658-67. PubMed ID: 10029595
[TBL] [Abstract][Full Text] [Related]
22. Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines.
Sartorius UA; Krammer PH
Int J Cancer; 2002 Feb; 97(5):584-92. PubMed ID: 11807782
[TBL] [Abstract][Full Text] [Related]
23. shRNA-mediated silencing of sorcin increases drug chemosensitivity in myeloma KM3/DDP and U266/ADM cell lines.
Xu P; Jiang YF; Wang JH
Int J Clin Exp Pathol; 2015; 8(3):2300-10. PubMed ID: 26045737
[TBL] [Abstract][Full Text] [Related]
24. Human melanoma cell lines selected in vitro displaying various levels of drug resistance against cisplatin, fotemustine, vindesine or etoposide: modulation of proto-oncogene expression.
Kern MA; Helmbach H; Artuc M; Karmann D; Jurgovsky K; Schadendorf D
Anticancer Res; 1997; 17(6D):4359-70. PubMed ID: 9494534
[TBL] [Abstract][Full Text] [Related]
25. Bcl-2 and Bcl-XL antagonize the mitochondrial dysfunction preceding nuclear apoptosis induced by chemotherapeutic agents.
Decaudin D; Geley S; Hirsch T; Castedo M; Marchetti P; Macho A; Kofler R; Kroemer G
Cancer Res; 1997 Jan; 57(1):62-7. PubMed ID: 8988042
[TBL] [Abstract][Full Text] [Related]
26. Targeting the miR-221-222/PUMA/BAK/BAX Pathway Abrogates Dexamethasone Resistance in Multiple Myeloma.
Zhao JJ; Chu ZB; Hu Y; Lin J; Wang Z; Jiang M; Chen M; Wang X; Kang Y; Zhou Y; Ni Chonghaile T; Johncilla ME; Tai YT; Cheng JQ; Letai A; Munshi NC; Anderson KC; Carrasco RD
Cancer Res; 2015 Oct; 75(20):4384-4397. PubMed ID: 26249174
[TBL] [Abstract][Full Text] [Related]
27. Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells.
Huang Y; Ibrado AM; Reed JC; Bullock G; Ray S; Tang C; Bhalla K
Leukemia; 1997 Feb; 11(2):253-7. PubMed ID: 9009089
[TBL] [Abstract][Full Text] [Related]
28. Expression of Bcl-2 in human epithelial tumor (HeLa) cells enhances clonogenic survival following exposure to 5-fluoro-2'-deoxyuridine or staurosporine, but not following exposure to etoposide or doxorubicin.
Elliott MJ; Stribinskiene L; Lock RB
Cancer Chemother Pharmacol; 1998; 41(6):457-63. PubMed ID: 9554589
[TBL] [Abstract][Full Text] [Related]
29. Diversity of the apoptotic response to chemotherapy in childhood leukemia.
Liu T; Raetz E; Moos PJ; Perkins SL; Bruggers CS; Smith F; Carroll WL
Leukemia; 2002 Feb; 16(2):223-32. PubMed ID: 11840289
[TBL] [Abstract][Full Text] [Related]
30. Fas (APO-1/CD95)-mediated apoptosis is independent of bcl-2: a study with cell lines overexpressing bcl-2 and with bcl-2 transfected cell lines.
Gazitt Y; Hu WX
Int J Oncol; 1998 Jan; 12(1):211-20. PubMed ID: 9454907
[TBL] [Abstract][Full Text] [Related]
31. Regulation of bcl-2, bcl-XL and bax in the control of apoptosis by hematopoietic cytokines and dexamethasone.
Lotem J; Sachs L
Cell Growth Differ; 1995 Jun; 6(6):647-53. PubMed ID: 7669718
[TBL] [Abstract][Full Text] [Related]
32. Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanism.
Dai Y; Landowski TH; Rosen ST; Dent P; Grant S
Blood; 2002 Nov; 100(9):3333-43. PubMed ID: 12384435
[TBL] [Abstract][Full Text] [Related]
33. Doxorubicin-resistant variants of human prostate cancer cell lines DU 145, PC-3, PPC-1, and TSU-PR1: characterization of biochemical determinants of antineoplastic drug sensitivity.
David-Beabes GL; Overman MJ; Petrofski JA; Campbell PA; de Marzo AM; Nelson WG
Int J Oncol; 2000 Dec; 17(6):1077-86. PubMed ID: 11078791
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis.
Alas S; Bonavida B
Clin Cancer Res; 2003 Jan; 9(1):316-26. PubMed ID: 12538484
[TBL] [Abstract][Full Text] [Related]
35. Antisense-mediated downregulation of anti-apoptotic proteins induces apoptosis and sensitizes head and neck squamous cell carcinoma cells to chemotherapy.
Sharma H; Sen S; Lo Muzio L; Mariggiò A; Singh N
Cancer Biol Ther; 2005 Jul; 4(7):720-7. PubMed ID: 15917659
[TBL] [Abstract][Full Text] [Related]
36. Imexon activates an intrinsic apoptosis pathway in RPMI8226 myeloma cells.
Dvorakova K; Payne CM; Landowski TH; Tome ME; Halperin DS; Dorr RT
Anticancer Drugs; 2002 Nov; 13(10):1031-42. PubMed ID: 12439337
[TBL] [Abstract][Full Text] [Related]
37. Molecular and cellular characterization of imexon-resistant RPMI8226/I myeloma cells.
Dvorakova K; Payne CM; Tome ME; Briehl MM; Vasquez MA; Waltmire CN; Coon A; Dorr RT
Mol Cancer Ther; 2002 Jan; 1(3):185-95. PubMed ID: 12467213
[TBL] [Abstract][Full Text] [Related]
38. Differential effects of chemotherapeutic agents on the Bcl-2/Bax apoptosis pathway in human breast cancer cell line MCF-7.
Leung LK; Wang TT
Breast Cancer Res Treat; 1999 May; 55(1):73-83. PubMed ID: 10472781
[TBL] [Abstract][Full Text] [Related]
39. Glucocorticoid cotreatment induces apoptosis resistance toward cancer therapy in carcinomas.
Herr I; Ucur E; Herzer K; Okouoyo S; Ridder R; Krammer PH; von Knebel Doeberitz M; Debatin KM
Cancer Res; 2003 Jun; 63(12):3112-20. PubMed ID: 12810637
[TBL] [Abstract][Full Text] [Related]
40. Thioredoxin peroxidase-1 (peroxiredoxin-1) is increased in thioredoxin-1 transfected cells and results in enhanced protection against apoptosis caused by hydrogen peroxide but not by other agents including dexamethasone, etoposide, and doxorubicin.
Berggren MI; Husbeck B; Samulitis B; Baker AF; Gallegos A; Powis G
Arch Biochem Biophys; 2001 Aug; 392(1):103-9. PubMed ID: 11469800
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
